Damoctocog alfa pegol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413456

CAS#: 1363853-26-2

Description: Damoctocog alfa pegol is a recombinant DNA-derived, Factor VIII concentrate medication used to treat hemophilia A. The most common side effects include headache, cough, nausea and fever.

Chemical Structure

Damoctocog alfa pegol
CAS# 1363853-26-2

Theoretical Analysis

MedKoo Cat#: 413456
Name: Damoctocog alfa pegol
CAS#: 1363853-26-2
Chemical Formula: C22H39N3O10S
Exact Mass: 537.2356
Molecular Weight: 537.63
Elemental Analysis: C, 49.15; H, 7.31; N, 7.82; O, 29.76; S, 5.96

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Damoctocog alfa pegol

IUPAC/Chemical Name: S-(1-(7-(2-methoxyethoxy)-14-oxo-2,5,9-trioxa-13-azahexadecan-16-yl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine


InChi Code: InChI=1S/C22H39N3O10S/c1-31-8-10-34-14-16(35-11-9-32-2)13-33-7-3-5-24-19(26)4-6-25-20(27)12-18(21(25)28)36-15-17(23)22(29)30/h16-18H,3-15,23H2,1-2H3,(H,24,26)(H,29,30)/t16?,17-,18?/m0/s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: to be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 537.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Paik J, Deeks ED. Damoctocog Alfa Pegol: A Review in Haemophilia A. Drugs. 2019 Jul;79(10):1147-1156. doi: 10.1007/s40265-019-01152-7. Erratum in: Drugs. 2019 Aug 23;: PMID: 31218660; PMCID: PMC6711950.

2: Paik J, Deeks ED. Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A. Drugs. 2019 Sep;79(13):1495. doi: 10.1007/s40265-019-01190-1. Erratum for: Drugs. 2019 Jul;79(10):1147-1156. PMID: 31444769; PMCID: PMC6728279.

3: Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol. 2020 Nov;99(11):2689-2698. doi: 10.1007/s00277-020-04280-3. Epub 2020 Sep 24. PMID: 32974838; PMCID: PMC7536163.

4: Fujii T, Kidoguchi Y, Takahashi N, Yu E, Ainiwaer D, Byrne A. Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan. J Med Econ. 2021 Jan-Dec;24(1):218-225. doi: 10.1080/13696998.2021.1875788. PMID: 33459088.

5: Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard- Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2020 Dec 9. doi: 10.1055/a-1333-5536. Epub ahead of print. PMID: 33296943.

6: Reding MT, Pabinger I, Lalezari S, Santagostino E, Mancuso ME. Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027. Haemophilia. 2020 Jul;26(4):e201-e204. doi: 10.1111/hae.13982. Epub 2020 Jun 23. PMID: 32578323; PMCID: PMC7496507.

7: Benson G, Morton T, Thomas H, Lee XY. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective. Clinicoecon Outcomes Res. 2021 Jan 18;13:39-51. doi: 10.2147/CEOR.S280574. PMID: 33500640; PMCID: PMC7822074.

8: Hakimi Z, Santagostino E, Postma MJ, Nazir J. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison. Adv Ther. 2021 Feb;38(2):1263-1274. doi: 10.1007/s12325-020-01599-1. Epub 2020 Dec 30. PMID: 33377987; PMCID: PMC7889532.